Scientists at Monash University in Australia have discovered two molecules that can fight asthma and lung function disorders associated with COVID-19. They can also be a possible lifesaver for people from respiratory distress syndrome. This is reported in an article published in the journal Nature Immunology.
The discovery was made during a study aimed at identifying the mechanisms of how the immune system interacts with the gut microbiome of genetically modified mice. It turned out that a byproduct of intestinal bacteria metabolism called p-cresol (PCS) led to strong protection against asthma. PCS itself is produced by reactions involving the amino acid L-tyrosine.
In addition, administration of PCS or L-tyrosine to mice provides significant protection against pneumonia. PCS acts on the epithelial cells lining the airways to also prevent allergic reactions in asthma. The molecules have been shown to be effective in animal models with acute respiratory distress syndrome, which is one of the causes of death in humans from coronavirus infection.
The research team has now begun developing a PCS-based drug with no potential side effects.
